2,758 Shares in Astera Labs, Inc. (NASDAQ:ALAB) Bought by PharVision Advisers LLC

PharVision Advisers LLC purchased a new stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,758 shares of the company's stock, valued at approximately $365,000.

Several other hedge funds have also bought and sold shares of ALAB. Park Avenue Securities LLC acquired a new position in shares of Astera Labs in the 4th quarter valued at $500,000. Dakota Wealth Management raised its position in shares of Astera Labs by 2.5% in the fourth quarter. Dakota Wealth Management now owns 43,110 shares of the company's stock worth $5,710,000 after acquiring an additional 1,049 shares during the period. Wesbanco Bank Inc. purchased a new stake in shares of Astera Labs during the 4th quarter worth about $331,000. Berbice Capital Management LLC acquired a new stake in shares of Astera Labs during the 4th quarter valued at about $86,000. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Astera Labs during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 60.47% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ALAB. Susquehanna initiated coverage on Astera Labs in a research report on Friday, May 16th. They set a "neutral" rating and a $80.00 price target on the stock. Citigroup reduced their target price on Astera Labs from $120.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Craig Hallum lifted their price target on shares of Astera Labs from $105.00 to $125.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Raymond James began coverage on shares of Astera Labs in a report on Friday, March 14th. They issued an "outperform" rating and a $82.00 price target for the company. Finally, Morgan Stanley upgraded shares of Astera Labs from an "equal weight" rating to an "overweight" rating and set a $99.00 price objective for the company in a research report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $100.00.

Astera Labs Price Performance

ALAB traded up $0.32 on Monday, reaching $94.62. 3,223,727 shares of the company's stock were exchanged, compared to its average volume of 3,988,631. Astera Labs, Inc. has a twelve month low of $36.22 and a twelve month high of $147.39. The stock has a market cap of $15.60 billion, a PE ratio of -54.69, a P/E/G ratio of 6.18 and a beta of 0.33. The stock's fifty day moving average price is $68.99 and its 200-day moving average price is $92.52.

Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.05. The firm had revenue of $159.44 million during the quarter, compared to analyst estimates of $151.55 million. Astera Labs had a negative net margin of 21.05% and a negative return on equity of 10.40%. Astera Labs's quarterly revenue was up 144.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. As a group, research analysts predict that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Insider Transactions at Astera Labs

In other news, General Counsel Philip Mazzara sold 25,000 shares of the business's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $90.13, for a total value of $2,253,250.00. Following the sale, the general counsel now directly owns 162,596 shares of the company's stock, valued at approximately $14,654,777.48. The trade was a 13.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sanjay Gajendra sold 165,000 shares of the stock in a transaction that occurred on Thursday, May 8th. The stock was sold at an average price of $71.76, for a total transaction of $11,840,400.00. Following the transaction, the insider now directly owns 755,000 shares of the company's stock, valued at $54,178,800. The trade was a 17.93% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 852,640 shares of company stock worth $69,893,694.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.